18 June 2026
18 June 2026
The study will enrol up to 40 participants across a maximum of five clinical sites in the US.
The trial is enrolling in the US and will include regions in the Asia Pacific, Europe, Latin America, and North America.
The companies aim to create a tablet-form treatment to improve the safety and absorption rates of peptide drugs.
The study aims to enrol about 150 patients across multiple sites.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
